Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

WTVB
wtvbam.com > 09/10/2026 > us-fda-pauses-new-enrollment-in-biohavens-epilepsy-drug-trials

US FDA pauses new enrollment in Biohaven’s epilepsy drug trials

4+ day, 1+ hour ago   (293+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug ​after rodent findings, sending its shares down more than ‌15% in early trading. • The U....

WTVB
wtvbam.com > 09/09/2026 > health-rounds-astrazeneca-drug-reduces-lung-disease-flare-ups-in-late-stage-trials

Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials

5+ day, 1+ hour ago   (872+ words) Sept 9 (Reuters) – Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona. A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers reported on…...

WTVB
wtvbam.com > 09/08/2026 > bristol-myers-blood-cancer-cell-therapy-meets-main-goal-in-mid-stage-trial

Bristol Myers’ blood cancer cell therapy succeeds in mid-stage trial

5+ day, 19+ hour ago   (257+ words) Sept 8 (Reuters) – Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, ​in patients with a hard-to-treat form of ‌blood cancer. The study evaluated the therapy, called arlocabtagene autoleucel, or…...

WTVB
wtvbam.com > 09/08/2026 > dyne-sarepta-shares-tumble-as-novartis-setback-weighs-on-muscle-disease-drug-developers

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

5+ day, 19+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

WTVB
wtvbam.com > 09/08/2026 > astrazenecas-cancer-drug-combo-hits-main-survival-goal-in-late-stage-trial

AstraZeneca’s cancer drug combo hits main survival goal in late-stage trial

5+ day, 23+ hour ago   (66+ words) WTVB AstraZeneca’s cancer drug combo hits main survival goal in late-stage trial Sept 8 (Reuters) – AstraZeneca said ​on Tuesday its cancer drug ​Imfinzi ⁠combined with ⁠Amgen’s targeted immunotherapy Imdelltra ​significantly ⁠improved ⁠overall survival ​in ​first-line extensive-stage small cell lung ⁠cancer in…...

WTVB
wtvbam.com > 09/08/2026 > novartis-announces-trial-setback-on-del-desiran-drug

Novartis announces trial setback on del-desiran drug

6+ day, 6+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

WTVB
wtvbam.com > 09/08/2026 > explainer-raids-shutdowns-warning-labels-indias-unprecedented-food-safety-push

Explainer-Raids, shutdowns, warning labels – India’s unprecedented food safety push

6+ day, 7+ hour ago   (652+ words) NEW DELHI, Sept 8 (Reuters) – India is witnessing an unprecedented food safety crackdown, with regulators forcing many local eateries and branded restaurants to suspend operations, while a push for front-of-pack warning labels has rattled the country’s more than $100 billion packaged food…...

wtvbam.com
wtvbam.com > 09/07/2026 > novo-scraps-two-more-heart-drug-trials-further-dimming-growth-beyond-obesity

Novo scraps two more heart drug trials, further dimming growth beyond obesity

1+ week, 34+ min ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...

WTVB
wtvbam.com > 09/04/2026 > ionis-novartis-key-experimental-heart-drug-fails-in-late-stage-trial

Novartis, Ionis’ experimental heart drug misses key goal in closely watched trial

1+ week, 2+ day ago   (464+ words) By Christy Santhosh and Bhanvi Satija Sept 4 (Reuters) – Novartis said on Friday its experimental drug pelacarsen did not cut the risk of major heart attacks and strokes in patients with a genetic risk factor in a late-stage trial, marking a…...

WTVB
wtvbam.com > 09/03/2026 > belgium-reports-about-3000-excess-deaths-over-summer-due-to-heat

Belgium reports about 3,000 excess deaths over summer due to heat

1+ week, 4+ day ago   (206+ words) BRUSSELS, Sept 3 (Reuters) – Heatwaves from June 18 through August 16 caused 2,935 excess deaths in Belgium, or 22.6% ​excess mortality, public health body ‌Sciensano said in a report on Thursday. • From June 18 through July 3, Belgium recorded its highest excess mortality, with 2,035 additional deaths, or…...